Mesa Labs reports Q3 adjusted EPS $2.02 vs $2.35 last year

Reports Q3 revenue $53.473M vs $54.287M last year. “Revenues of $53,473 for the quarter decreased 1.5% as compared to the third quarter of fiscal year 2023, due primarily to a 9.0% core organic revenues decrease which was mostly offset by $3,837 from the GKE acquisition. The full benefit of the GKE acquisition will not be recognized until the upcoming quarter as the GKE entities were acquired at various times during 3Q24. Revenues headwinds were comprised of capital equipment placements in the Biopharmaceutical Development division remaining well below recent history and the ongoing economic slowdown and broad healthcare anti-corruption initiatives in China, which began to significantly impact our Clinical Genomics Division during 3Q24, both of which were partially offset by core organic growth in the Calibration Solutions division,” said Gary Owens, Chief Executive Officer of Mesa.